Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 94.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,409 shares of the biopharmaceutical company's stock after selling 127,571 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Agios Pharmaceuticals were worth $329,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals during the second quarter worth about $40,000. CWM LLC boosted its stake in shares of Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 1,836 shares during the period. North Star Asset Management Inc. acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $216,000. Finally, XTX Topco Ltd purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $230,000.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO traded down $0.04 during trading on Monday, reaching $44.83. The company's stock had a trading volume of 658,210 shares, compared to its average volume of 689,513. Agios Pharmaceuticals, Inc. has a twelve month low of $20.40 and a twelve month high of $53.28. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of 3.95, a P/E/G ratio of 0.45 and a beta of 0.75. The business's fifty day moving average price is $44.62 and its 200-day moving average price is $42.32.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a net margin of 2,051.38% and a negative return on equity of 3.81%. The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. During the same period in the previous year, the firm posted ($1.51) EPS. The company's revenue for the quarter was up 28.4% on a year-over-year basis. As a group, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post 7.54 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Leerink Partnrs lowered Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 27th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Scotiabank increased their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a "sector outperform" rating in a report on Friday. Raymond James reaffirmed an "outperform" rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $52.33.

Insiders Place Their Bets

In other news, CEO Brian Goff sold 11,091 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares of the company's stock, valued at approximately $3,368,358. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Brian Goff sold 11,091 shares of the firm's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company's stock, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is owned by insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.